News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
News J&J to "price responsibly", says CEO post Trump meeting Gorsky promises "transparency report" on pricing.
News AbbVie bullish on Humira and near-term pipeline Sales of Humira could peak above $18 billion - CEO
News Roche's Mabthera faces cut-price competition in EU Blockbuster likely to face cheap near-copy for first time.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
